PhaseBio Pharmaceuticals, Inc. (PHAS) financial statements (2023 and earlier)

Company profile

Business Address 1 GREAT VALLEY PARKWAY
MALVERN, PA 19355
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments41,80028,12274,02561,031
Cash and cash equivalents41,80028,12274,02561,031
Restricted cash and investments   20
Receivables  1,233233
Other undisclosed current assets6,98412,0273,5651,344
Total current assets:48,78440,14978,82362,628
Noncurrent Assets
Operating lease, right-of-use asset1,4691,9271,715
Property, plant and equipment10,2308,2241,924355
Other noncurrent assets57573243
Total noncurrent assets:11,75610,2083,671398
TOTAL ASSETS:60,54050,35782,49463,026
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities20,9239,6056,1014,577
Accounts payable12,5703,6742,9211,806
Accrued liabilities8,3535,9313,1802,771
Deferred revenue1,547  
Debt5,4135,3552,378 
Total current liabilities:27,88314,9608,4794,577
Noncurrent Liabilities
Long-term debt and lease obligation2,4328,32113,8347,500
Long-term debt, excluding current maturities1,3596,77312,3267,500
Operating lease, liability1,0731,5481,508
Liabilities, other than long-term debt123,25952,27820322
Deferred revenue7,622  
Deferred rent credit   22
Other liabilities794559203 
Derivative instruments and hedges, liabilities114,84351,719  
Total noncurrent liabilities:125,69160,59914,0377,522
Total liabilities:153,57475,55922,51612,099
Stockholders' equity
Stockholders' equity attributable to parent(93,034)(25,202)59,97850,927
Common stock48292925
Treasury stock, value(24)(24)(24)(24)
Additional paid in capital298,736235,516222,131173,837
Accumulated deficit(391,794)(260,723)(162,158)(122,911)
Total stockholders' equity:(93,034)(25,202)59,97850,927
TOTAL LIABILITIES AND EQUITY:60,54050,35782,49463,026

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues10,8313202,361668
Gross profit:10,8313202,361668
Operating expenses(118,193)(85,176)(42,097)(20,312)
Operating loss:(107,362)(84,856)(39,736)(19,644)
Nonoperating income (expense)(22,109)(13,466)489(4,202)
Other nonoperating income (expense)(22,109)(13,709)489(4,202)
Interest and debt expense(947)(1,445)(1,076)(3,924)
Loss from continuing operations before equity method investments, income taxes:(130,418)(99,767)(40,323)(27,770)
Other undisclosed income from continuing operations before income taxes947   
Loss from continuing operations before income taxes:(129,471)(99,767)(40,323)(27,770)
Income tax expense(1,600)   
Loss before gain (loss) on sale of properties:(131,071)(99,767)(40,323)(27,770)
Other undisclosed net income 1,2021,0763,924
Net loss available to common stockholders, diluted:(131,071)(98,565)(39,247)(23,846)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(131,071)(98,565)(39,247)(23,846)
Comprehensive loss, net of tax, attributable to parent:(131,071)(98,565)(39,247)(23,846)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: